Abstract
The first reported imaging studies with radio-labelled antibodies of head and
neck cancer patients were published at the halfway of 1980s. Started with polyclonal
anti-CEA antibody, the anti-CEA monoclonal antibody was followed shortly thereafter
in the radioimmunoscintigraphy imaging of head and neck tumor patients. Despite a
promising platform, the pilot-antibody studies in the latter part of the last millennium
have in the end, not yielded a clear advantage or benefit to support clinical decisionmaking
by RIS imaging method in head and neck tumors, neither in terms of diagnostic
imaging nor in terms of treatments. The investigated antibodies have not been shown to
be sufficiently selective in identifying head and neck tumors.
Keywords: Anti-CEA-antibody, Friendship, Head and neck Tumor, Immunoscintigraphy, Radioisotope.
Related Books
Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine
Cancer Metastasis and Cancer Stem Cell/Niche
Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature
Controversies in Neuro-Oncology
Current Advances in Breast Cancer Research: A Molecular Approach
Cutting Edge Therapies for Cancer in the 21st Century
Frontiers in Cancer Immunology
Frontiers in Cancer Immunology
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Frontiers in Clinical Drug Research - Anti-Cancer Agents